Preoperative simultaneous combined radiotherapy and chemotherapy with mainly composed of CDDP in oral cancer.

概要

論文の詳細を見る
Thirty-six patients with squamous cell carcinoma of the oral region were treated preoperatively with CDDP (15mg/mm2×3days), PEP (5mg/body×4days) or CBDCA (70-100mg/mm2×3days), 5 FU (500-750mg/body×4days) in combination with simultaneous radiation (30-40Gy).<BR>Thirty-three patients (91.2%) had Stage III or IV carcinomas whereas 3 patients had Stage II lesions. The clinical response was vary encouraging: 22 patients (61.1%) achieved CR, 13 patients (36.1%) were judged as PR, only one patient (2.8%) was NC, and over all response rates were 97.2%. Histological effects were seen in 33/36 (91.7%) (9 as Grade IIB, 8 as Grade III, 16 as Grade IV according to Shimosato's classification.) and especially 72.7% of CR were histologically negative for tumor. Side effects of this therapy were minimal and reversible. With a follow-up ranging from 8-76 months, 5-year cumulative survival rates are 81.5% for all patients, and 100% as Stage II, 87.4% as Stage III, 72.8% as Stage IV, respectively. Morbidity after subsequent curative surgery is none, and histologic complete reponse are frequent. This preoperative combined simultaneous chemoradiotherapy appeares a highly active and well tolerated regimen for even advanced and highly malignant carcinomas of the oral cavity.
日本頭頸部癌学会の論文